AstraZeneca (AZN) has struck a wide-ranging obesity and type 2 diabetes deal with China鈥檚 CSPC Pharmaceuticals (HK:1090).
The pharma giant will pay CSPC $1.2bn (拢870mn) upfront, with further development milestones of up to $3.5bn, plus commercial payments and royalties.
AstraZeneca鈥檚 presence in weight loss drugs is less advanced than competitors like Eli Lilly (US: LLY) or Novo Nordisk (DK:NOVOB), but it has been building up a portfolio of next generation 鈥渋ncretin鈥 medicines that aim for better tolerability and muscle preservation.
The obesity deal also follows AstraZeneca鈥檚 recent announcement that it plans to invest $15bn in China through to 2030 in expanding R&D, manufacturing and deals with local companies in a sign of the country鈥檚 growing importance in early-stage drug development.
The agreement also builds on a strategic research collaboration signed last year, when AstraZeneca paid $110mn to work with CSPC on AI-driven drug discovery, with more than $5bn of potential milestones attached.




